Drug Trial Radar · NCT00144105
A Randomised Trial to Evaluate the Antiviral Efficacy and Safety of Treatment With 500 mg Tipranavir (TPV) Plus 100 mg or 200 mg Ritonavir (RTV) p.o. BID in Comparison to 400 mg Lopinavir (LPV) Plus 100 mg RTV p.o. BID in Combination With Standard Background Regimen in ARV Therapy naïve Patients.
Last checked: Nov 20, 2026Latest source record: Nov 1, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
562
Actual
Start
Feb 2004
Primary completion
Nov 2006
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Sep 5, 2005
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Evaluation of safety and efficacy of Tipranavir (TPV) boosted with Ritonavir (RTV) versus an active control arm (Lopinavir / RTV) in antiretroviral (ARV) therapy naïve HIV-1 infected patients
Conditions
- HIV Infections
Interventions
TPV500mg/RTV200mgBIDDrug
TPV500mg/RTV100mgBIDDrug
LPV400mg/RTV100mgBIDDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary endpoint is the proportion of treatment responders at 48 weeks. A treatment responder is a patient with a viral load (VL) less than 50 copies/mL measured at two consecutive visits without prior rebound or change of ARV therapy.
Locations
81 sites in 15 countries. Site status is shown where the registry gives one.
Boehringer Ingelheim Investigational Site
BsAs, Argentina
Fundacion Huesped
Buenos Aires, Argentina
Hospital de Agudos Teodoro Alvarez
Buenos Aires, Argentina
Hospital Posadas
Haedo, Argentina
Boehringer Ingelheim Investigational Site
Darlinghurst, New South Wales, Australia
St Vincents Hospital;
Darlinghurst, New South Wales, Australia
Boehringer Ingelheim Investigational Site
Liverpool, New South Wales, Australia
Boehringer Ingelheim Investigational Site
Surry Hills, New South Wales, Australia
Boehringer Ingelheim Investigational Site
Carlton, Victoria, Australia
Alfred Hospital
Melbourne, Victoria, Australia
Boehringer Ingelheim Investigational Site
South Yarra, Victoria, Australia
Unidade de Pesquisa Clínica (UPC) - AIDS
Campinas - Sp, Brazil
Boehringer Ingelheim Investigational Site
Curitiba - PR, Brazil
Boehringer Ingelheim Investigational Site
Manguinhos - Rio de Janeiro - RJ, Brazil
Instituto de Crianca / Hospital das Clínicas-FMUSP
Mooca / São Paulo, Brazil
Hospital Geral de Nova Iguaçu - Ministério da Saúde
Nova Iguaçu - RJ, Brazil
Universidade Federal do Rio de Janeiro
Rio de Janeiro - RJ, Brazil
Hospital Dia
Sacoma - São Paulo, Brazil
Universidade Federal da Bahia-Unidade Docente Assistencial d
Salvador - BA, Brazil
Boehringer Ingelheim Investigational Site
Santos - Sp, Brazil
Hospital do Servidor Público Estadual de São Paulo
São Paulo - Sp, Brazil
UNIFESP/ Hospital São Paulo- Univers. Federal de São Paulo
São Paulo - Sp, Brazil
I.I. Emilio Ribas - Moléstias Infecciosas
São Paulo - SP, Brazil
Instituto de Infectologia Emílio Ribas
São Paulo - SP, Brazil
Centro de Referência e Treinamento - DST/AIDS
Vila Mariana - Sao Paulo, Brazil
Downtown Infectious Diseases Clinic
Vancouver, British Columbia, Canada
Boehringer Ingelheim Investigational Site
Winnipeg, Manitoba, Canada
McMaster University Medical Centre
Hamilton, Ontario, Canada
The Ottawa Hospital Riverside Campus
Ottawa, Ontario, Canada
Canadian Immunodeficiency Research Collaborative Inc.
Toronto, Ontario, Canada
St. Michael's Hospital
Toronto, Ontario, Canada
Sunnybrook & Woman's College Health Science Centre
Toronto, Ontario, Canada
Toronto General Hospital
Toronto, Ontario, Canada
Boehringer Ingelheim Investigational Site
Whitby, Ontario, Canada
Montreal General Hospital - McGill University Health Centre
Monteal, Quebec, Canada
Boehringer Ingelheim Investigational Site
Montreal, Quebec, Canada
Montreal Chest Institute, McGill University Health Centre
Montreal, Quebec, Canada
Boehringer Ingelheim Investigational Site
Bogotá, Colombia
Hôpital Jean Verdier
Bondy, France
Hôpital Bocage
Dijon, France
Showing 40 of 81 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.